ArticleBlood2021

The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.

Guang Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.